Use of Clorhexidine Dressings to Reduce Surgical Site Infections in Breast Cancer Surgery. A Controlled Clinical Trial
Breast Cancer
About this trial
This is an interventional prevention trial for Breast Cancer focused on measuring Drain antisepsis, Bacterial colonization, Surgical site infection
Eligibility Criteria
Inclusion Criteria:
- Females minimum age 18 able to give informed consent
- Breast cancer confirmed by histopathology
- Patients undergoing unilateral or bilateral mastectomy with or without immediate expander reconstruction.
Exclusion Criteria:
- Males
- Patients who deny informed consent
- Prior radiation therapy to the sick breast.
- Pregnant or breastfeeding women
- Patients undergoing immediate breast reconstruction with Deep Inferior
- Epigastric Perforator (DIEP) o Transverse Rectus Abdominal Muscle techniques (TRAM) .
- Emergency procedures
- Documented allergy to chlorhexidine gluconate
- Antibiotic use in the fourteen days prior to surgical date
- Patients with a history or suspicion of breast cancer surgery outside the INCan in the previous three months.
- Patients who do not speak spanish, diagnosed with a psychiatric disorder and in whom a minimum follow-up of 14 days couldn't be feasible because of operative difficulties (eg.
place of residence or reference to other health institutions).
Sites / Locations
- Instituto Nacional de Cancerología
Arms of the Study
Arm 1
Arm 2
Experimental
No Intervention
Antiseptic occlusive dressing group
Standard care
A chlorhexidine gluconate occlusive adhesive dressing (Tegaderm CHG) will be applied to the intervention drain sites and changed every seven days.
Standard drain care will be performed twice a day or three times if bulb is full and needs to be emptied. Standard drain care consists of stripping the tubing, emptying the drainage bulb, recording the volume of fluid, and cleaning the drain site and the tubing with a cotton swab dipped in rubbing alcohol.